ATAI Beckley Inc (ATAI)

Currency in USD
7.170
-0.010(-0.14%)
Real-time Data·
Advertisement
Earnings results expected in 8 days
ATAI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.1607.180
52 wk Range
3.2657.220
Key Statistics
Prev. Close
7.18
Open
7.16
Day's Range
7.16-7.18
52 wk Range
3.265-7.22
Volume
3.96M
Average Volume (3m)
11.5M
1-Year Change
68.1925%
Book Value / Share
0.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.588
Upside
+33.72%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

ATAI Beckley Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

3 Buy
11 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 9.588
(+33.72% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Hold7.50+4.68%-Downgrade20/07/2026
Berenberg
Hold---Downgrade20/07/2026
TD Cowen
Hold---Downgrade17/07/2026
Jefferies
Hold7.50+4.68%10.00Downgrade17/07/2026
Jones Trading
Hold---Downgrade16/07/2026

Earnings

Latest Release
12/05/2026
EPS / Forecast
-0.08 / -0.10
Revenue / Forecast
954K / 140K
EPS Revisions
Last 90 days

Compare ATAI to Peers and Sector

Metrics to compare
ATAI
Peers
Sector
Relationship
P/E Ratio
−4.0x−9.1x−0.4x
PEG Ratio
0.020.520.00
Price/Book
13.4x2.3x2.6x
Price / LTM Sales
760.5x229.6x3.0x
Upside (Analyst Target)
18.4%26.6%54.3%
Fair Value Upside
Unlock−0.2%8.4%Unlock

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
50.38M13.62%361.75M
Other Institutional Investors
142.31M38.47%1.02B
Public Companies & Retail Investors
177.26M47.91%1.27B
Total
369.95M100.00%2.66B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Apeiron Investment Group Limited14.59%53,971,646387,516
BlackRock, Inc.6.76%24,994,078179,457

People Also Watch

11.69
CMPS
+3.91%
29.13
GHRS
+3.33%
23.01
FLY
+5.12%
26.485
UMAC
+14.75%
135.415
AAOI
+22.87%

FAQ

What Is the ATAI Beckley (NASDAQ: ATAI) Share Price Today?

The ATAI Beckley stock price today is 7.170 USD.

What Stock Exchange Does ATAI Beckley (ATAI) Trade On?

ATAI Beckley is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for ATAI Beckley?

The stock symbol (also called a 'ticker') for ATAI Beckley is "ATAI."

What Is the Current ATAI Beckley Market Capitalisation?

As of today, ATAI Beckley (NASDAQ: ATAI) market cap is 2.650B USD.

What Is ATAI Beckley's (ATAI) Earnings Per Share (TTM)?

The ATAI Beckley EPS is currently -2.441 (Trailing Twelve Months).

When Is the Next ATAI Beckley Earnings Date?

ATAI Beckley's next earnings report will be released on 12/08/2026.

Is ATAI a Buy or Sell From a Technical Analyst Perspective?

Based on today's ATAI Beckley moving averages and other technical indicators, the daily buy/sell signal for ATAI stock is Strong Buy.

How Many Times Has ATAI Beckley Stock Split?

ATAI Beckley has split 0 times. (See the ATAI stock split history page for full effective split date and price information.)

How Many Employees Does ATAI Beckley Have?

ATAI Beckley has 99 employees, based on their latest Companies House report.

What is the current trading status of ATAI Beckley (NASDAQ: ATAI)?

As of 04/08/2026, ATAI Beckley (ATAI) is trading at a share price of 7.170 USD, with a previous close of 7.180 USD. The stock has fluctuated within a day range of 7.160 USD to 7.180 USD, while its 52-week range spans from 3.265 USD to 7.220 USD.

What Is ATAI Beckley (ATAI) Price Target According to Analysts?

The average 12-month price target for ATAI Beckley is 9.588 USD, with a high estimate of 16 USD and a low estimate of 7.45 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +33.72% Upside potential.

What Is the ATAI Premarket Price?

ATAI's last pre-market stock price is 7.160 USD. The pre-market share volume is 46,760.000, and the stock has decreased by -0.020, or -0.280%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.